item management s discussion and analysis of financial condition and results of operations critical accounting policies the discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements  which have been prepared in accordance with accounting principles generally accepted in the united states 
the preparation of these financial statements requires management to make estimates and assumptions in certain circumstances that affect the reported amount of assets and liabilities  revenues and expenses  and related disclosure of contingent assets and liabilities at the date of our financial statements 
management bases its estimates and judgments on historical experience  observance of trends in the industry  information provided by customers and other outside sources and on various other factors that are believed to be reasonable under the circumstances 
actual results may differ from these estimates under different assumptions or conditions 
revenue recognition the company s revenues are recognized when products are shipped to or otherwise accepted by unaffiliated customers pursuant to customers orders  the price is defined and collection is reasonably assured 
the securities and exchange commission s staff accounting bulletin sab no 
 revenue recognition provides guidance on the application of generally accepted accounting principles to selected revenue recognition issues 
the company has concluded that its revenue recognition policy is appropriate and in accordance with generally accepted accounting principles and sab no 
allowance for uncollectible accounts receivable accounts receivable are reduced by an allowance for amounts that may become uncollectible in the future 
the company extends credit to customers in the normal course of business  but generally does not require collateral or any other security to support amounts due 
management performs on going credit evaluations of its customers and bases the estimated allowance on these evaluations 
inventories inventories are stated at the lower of cost first in  first out method or market and have been reduced to the lower of cost or market for obsolete  excess or unmarketable inventory 
the lower of cost or market adjustment is based on management s review of inventories on hand compared to estimated future usage and sales 
goodwill  intangible and other long lived assets intangible and certain other long lived assets with a definite life are amortized over their useful lives 
useful lives are based on management s estimates of the period that the assets will generate revenue 
the company does not amortize goodwill and reviews goodwill for impairment on a regular basis  at least annually 
management has reviewed goodwill and other intangibles for impairment and has concluded that such assets are appropriately valued at the financial statement date 
general the company manufactures biomaterials and medical devices for use in various surgical markets and provides related specialized contract aseptic manufacturing services 
the company operates through two business units  the hyaluronan division and the oral restorative division 

table of contents the company has a number of relationships with corporate partners relating to the development and marketing of hyaluronan based products for a variety of medical applications 
currently  the primary commercial application for the company s hyaluronan is as a component in ophthalmic surgical products marketed by alcon for cataract surgery 
sales to alcon are made under a supply agreement that extends through december  the agreement contains minimum purchase requirements totaling million in each of calendar years and ethicon began marketing intergel solution outside the united states in june the company received fda approval to market intergel solution in the united states in november  and ethicon began marketing it in the united states during the first calendar quarter of intergel solution was voluntarily withdrawn from the market by ethicon in march in order to complete an assessment of information obtained during postmarketing experience with the product  including allegations of adverse events associated with off label use in non conservative surgical procedures such as hysterectomies 
the company is working with ethicon to complete the post marketing evaluation and determine the opportunities for returning the product to market 
the company s oral restorative division markets a comprehensive line of titanium based dental implants for tooth replacement therapy 
the oral restorative division also manufactures and markets synthetic bone graft substitute products for the restoration of bone tissue deterioration resulting from periodontal disease and tooth loss 
the oral restorative division also markets other products for the regeneration of bone and soft tissue 
the division s products are marketed in the united states through the company s direct sales force  in italy through the company s subsidiary  lifecore biomedical spa  in germany through the company s subsidiary  lifecore biomedical gmbh  in scandinavia through the company s subsidiary  lifecore biomedical ab  and in other countries through distributors 
results of operations year ended june  compared with year ended june  hyaluronan oral restorative division division consolidated net sales cost of goods sold gross profit operating expenses research and development marketing and sales general and administrative restructuring charges operating income loss net sales 
net sales increased  or in fiscal from fiscal hyaluronan division sales increased  and oral restorative division sales increased  or 
hyaluronan division sales increased to  in fiscal from  in fiscal due to increased sales of ophthalmic and veterinary products 
sales of ophthalmic products to a single customer were  in fiscal compared with  for fiscal this sales increase was partially offset by a reduction in intergel solution sales due to ethicon s voluntary withdrawal of intergel solution from the market 
oral restorative division sales increased to  in fiscal from  in fiscal domestic sales increased due to the continued expansion of our sales representatives  the introduction of the renova internal hex implant system and growth in market acceptance of the stage single stage implant system 
sales in the international markets increased by due to sales increases at our subsidiary operations and a favorable impact from currency translations 

table of contents gross profit 
consolidated gross profit  as a percentage of net sales  was in fiscal and in fiscal the gross profit for the hyaluronan division increased to in fiscal from in fiscal the increase in gross profit is due to a favorable product mix and cost savings  partially offset by an increase in unused manufacturing capacity charges associated with decreased hyaluronan production 
gross profit for the oral restorative division increased to in fiscal from in fiscal due to sales mix  reduced discounting and lower material costs 
research and development 
research and development expenses increased  or in fiscal from fiscal the increase is due to additional consulting and professional fees associated with the market withdrawal of intergel solution in march marketing and sales 
marketing and sales expenses increased by  or in fiscal from fiscal the increase was due mainly to costs associated with the expansion of the oral restorative s domestic sales force and international operations 
general and administrative 
general and administrative expenses increased by  or in fiscal from fiscal the increase is principally related to increases in legal  insurance  subsidiary operations and sarbanes oxley compliance costs 
restructuring charges 
restructuring charges of  were recorded as part of a workforce reduction 
the restructuring charges consisted of  for employee severance costs and  for professional fees 
other income expense 
net other expense  as shown on the condensed consolidated statements of operations  decreased  for the current fiscal year as compared to the last fiscal year 
the decrease is due to the  increase in currency transaction gains realized on euro denominated intercompany transactions and a reduction of interest expense of  year ended june  compared with year ended june  hyaluronan oral restorative division division consolidated net sales cost of goods sold gross profit operating expenses research and development marketing and sales general and administrative operating income loss net sales 
net sales increased  or in fiscal from fiscal hyaluronan division sales increased  or  and oral restorative division sales increased  or 
hyaluronan division sales increased to  in fiscal from  in fiscal due to increased sales of ophthalmic and orthopedic products 
sales of ophthalmic products to a single customer were  in fiscal compared with  for fiscal this sales increase was partially offset by a reduction in intergel solution sales due to ethicon s voluntary withdrawal of intergel solution from the market 

table of contents oral restorative division sales increased to  in fiscal from  in fiscal domestic sales increased due to continued growth in market acceptance of the stage single stage implant system and the rbm coated implant lines 
sales in the international markets increased by due to sales increases at our subsidiary operations and a favorable impact from currency translations 
gross profit 
consolidated gross profit  as a percentage of net sales  was in fiscal and in fiscal the gross profit for the hyaluronan division increased to in fiscal from in fiscal the increase in gross profit is due to absorption of unused manufacturing capacity charges associated with increased hyaluronan production and product mix 
gross profit for the oral restorative division increased to in fiscal from in fiscal due to sales mix and reduced material costs 
research and development 
research and development expenses decreased  or in fiscal from fiscal the decrease is due to the decline in consulting and professional fees related to the regulatory review process of intergel solution which received fda approval in fiscal marketing and sales 
marketing and sales expenses increased by  or in fiscal from fiscal the increase was due mainly to costs associated with the international expansion of the oral restorative business 
general and administrative 
general and administrative expenses increased by  or in fiscal from fiscal the increase is principally related to costs associated with subsidiary operations and higher legal expenses in the fiscal year as compared to the fiscal year 
other income expense 
net other expense decreased  for the fiscal year as compared to the fiscal year 
the decrease is primarily due to the  increase in other income from currency gains realized on euro denominated intercompany transactions 
liquidity and capital resources inventories consist mainly of finished hyaluronan powder and oral restorative products and related raw materials 
the portion of finished hyaluronan inventory that is not expected to be consumed within the next twelve months is classified as long term inventory 
the finished hyaluronan inventory is maintained in a frozen state and has a shelf life of ten years 
total inventory decreased by  and  in fiscal and  respectively  as the company decreased production of hyaluronan powder 
the company had positive cash flow from operations in fiscal  and charges for unused manufacturing capacity associated with the company s hyaluronan production  additional costs associated with the withdrawal of intergel solution from the market  and restructuring charges have negatively impacted operating results in the current fiscal year 
also  marketing and sales expenses for the oral restorative products are expected to continue at a high level due to continued international expansion and increased personnel costs 
prior to the current fiscal year  charges for unused capacity were due to an unanticipated delay in receiving intergel solution marketing approval in the united states from the fda 
in october  the company issued an aggregate of  shares of common stock to lancet as the final payment under a consulting agreement 
the number of shares issued to lancet was determined using a formula based on the quoted market value of the common stock as determined on the nasdaq national market 
under the terms of the agreement  lancet exercised the right to have the shares registered for sale 
a registration statement on form s was filed and declared effective by the securities and exchange commission in november the loan agreement between the company and the holder of the industrial development revenue bonds issued to finance the company s chaska  minnesota facility was amended in june to waive the fixed charge coverage ratio and the cash flow coverage ratio through june  on july   the company gave notice to the bond trustee of its intention to redeem the bonds on september  the company repaid the existing bonds with the proceeds of a new issuance of industrial revenue bonds which closed on august  the aggregate principal amount of the new bonds is  and the bonds will bear interest at a variable rate set weekly by the bond remarketing agent on date of closing 
in addition  the company will pay an annual remarketing fee equal to 
and an annual letter of credit fee of 

table of contents the company has a  credit facility with a bank which has a maturity date of december  the agreement allows for advances against eligible accounts receivable and inventories  subject to a borrowing base certificate 
interest is accrued at the prime rate at june  and  which was and  respectively 
at june  and  there were no balances outstanding under the line of credit 
the terms of the agreement require the company to comply with various financial covenants including minimum tangible net worth  liabilities to tangible net worth ratio and net income loss 
at june  and  the company was in compliance with all covenants 
the company s ability to generate positive cash flow from operations and achieve ongoing profitability is dependent upon the continued expansion of revenue from its hyaluronan and oral restorative businesses 
growth in the hyaluronan division is unpredictable due to the uncertainty associated with the future market status of intergel solution  the complex governmental regulatory environment for new medical products and the early stage of certain of these markets 
similarly  expansion of the company s oral restorative division sales is also dependent upon increased revenue from new and existing customers  as well as successfully competing in a more mature market 
the company expects its cash generated from anticipated operations and the availability under the line of credit to satisfy cash flow needs in the near term 
no assurance can be given that the company will maintain positive cash flow from operations 
while the company s capital resources appear adequate today  the company may seek additional financing in the future 
if additional financing is necessary  no assurance can be given that such financing will be available and  if available  will be on terms favorable to the company and its shareholders 
contractual obligations the company s off balance sheet financing activities consist of operating leases for office equipment 
see the amount of contractual obligations for operating leases in the table below 
the effect of these operating leases is not material 
payments due by period for our contractual obligations at june  are as follows payments due by period less than total year to years to years thereafter long term debt operating leases purchase obligations total subsequent to the end of the year  on august   the company issued variable rate industrial revenue bonds 
the proceeds from these bonds were used to retire the existing fixed rate industrial revenue bonds on september  the new bond obligation is  and the variable interest rate at the date of issuance was 
the five year scheduled maturity of this new issuance beginning and ending in is      and  thereafter 
cautionary statement statements included in this management s discussion and analysis of financial condition and results of operations and elsewhere in this form k  in the letter to shareholders contained in the annual report to shareholders  in future filings by the company with the securities and exchange commission and in the company s press releases and oral statements made with the approval of authorized executive officers  if the statements are not historical or current facts  should be considered forward looking statements made pursuant to the safe harbor provisions of the private securities litigation reform act of such forward looking statements relate to market acceptance and demand for the company s products  future product development plans and timing  the results of clinical trials  fda clearances and the related timing of such  the potential size of the markets for the company s products  future product introductions  future revenues  expense levels and capital needs and the company s ability to successfully negotiate acceptable agreements with its corporate partners 
these statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical earnings and those presently anticipated or projected 
the company wishes to caution readers not to place undue reliance on any such forward looking statements  which speak only as of the date made 
the following important factors  among others  in some cases have affected and in the future could affect the company s actual results and could cause its actual financial performance to differ materially from that expressed in any forward looking statement i the uncertainty associated with the future market status of intergel 
table of contents solution  ii obtaining the necessary regulatory approvals for new hyaluronan and oral restorative products  iii the company s reliance on corporate partners to develop new products on a timely basis and to market the company s existing and new hyaluronan products effectively  iv intense competition in the markets for the company s principal products and v other factors discussed in the risk factors filed as exhibit to this form k 
the foregoing list should not be construed as exhaustive  and the company disclaims any obligation subsequently to revise any forward looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events 
item a 
quantitative and qualitative disclosures about market risk the company invests its excess cash in money market mutual funds and highly rated short term corporate debt securities 
all investments are held to maturity 
the market risk on such investments is minimal 
receivables from sales to foreign customers are denominated in us dollars 
transactions at the company s foreign subsidiaries are denominated in european euros at lifecore biomedical spa and lifecore biomedical gmbh and are denominated in swedish krona at lifecore biomedical ab 
the company is exposed to foreign currency exchange rate risk arising from transactions in the normal course of business from sales to its foreign subsidiaries 
because the company s products are manufactured or sourced primarily from the united states  a stronger us dollar generally has a negative impact on results from operations outside the united states while a weaker dollar generally has a positive effect 
the company does not use derivative financial instruments to manage foreign currency fluctuation risk 
at june   the company s outstanding long term debt carries interest at a fixed rate 
as a result  there is no material market risk 
however  the company will repay the existing bonds with the proceeds of a new issuance of industrial revenue bonds on september  the aggregate principal amount of the new bonds is  and the new bonds will bear interest at a variable rate set weekly by the bond remarketing agent 
the effective rate on august  was 
a ten percent change in this variable rate would be approximately  annually 

table of contents 
